ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $3.30.

A number of equities analysts have commented on the stock. Wall Street Zen lowered shares of ALX Oncology from a “hold” rating to a “sell” rating in a report on Friday, June 6th. HC Wainwright dropped their target price on shares of ALX Oncology from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, UBS Group dropped their target price on shares of ALX Oncology from $1.20 to $1.00 and set a “buy” rating for the company in a research report on Wednesday, May 21st.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $0.50 on Friday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $26.54 million, a price-to-earnings ratio of -0.20 and a beta of 1.11. The firm’s fifty day simple moving average is $0.48 and its 200 day simple moving average is $0.87. ALX Oncology has a twelve month low of $0.40 and a twelve month high of $8.78.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.11). As a group, equities research analysts expect that ALX Oncology will post -2.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors have recently modified their holdings of the business. Almitas Capital LLC grew its position in shares of ALX Oncology by 10.6% during the 1st quarter. Almitas Capital LLC now owns 1,353,141 shares of the company’s stock valued at $843,000 after buying an additional 130,196 shares during the last quarter. Acadian Asset Management LLC boosted its stake in ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after purchasing an additional 186,883 shares during the period. Bank of America Corp DE boosted its stake in ALX Oncology by 492.9% during the 4th quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock valued at $1,729,000 after purchasing an additional 860,703 shares during the period. Bank of Montreal Can acquired a new position in ALX Oncology during the 4th quarter valued at about $1,380,000. Finally, Two Sigma Advisers LP boosted its stake in ALX Oncology by 64.6% during the 4th quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock valued at $1,376,000 after purchasing an additional 323,400 shares during the period. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.